Browsing Tag
Moderna
36 posts
US medical groups fill CDC policy gap with independent 2026-27 respiratory vaccine recommendations
Major US medical groups issue independent flu, COVID-19 and RSV vaccine guidance as the traditional CDC recommendation process remains unsettled.
Moderna proposes $2bn zero-coupon notes as oncology success reshapes capital strategy
Moderna plans a $2 billion private placement of zero-regular-interest convertible notes due 2032, with a possible additional $300 million and capped-call protection designed to reduce dilution as the company prepares for increased oncology investment.
Immatics skips interim anzu-cel analysis and adds 90 patients ahead of pivotal 2027 verdict
Immatics adds 90 patients to anzu-cel Phase 3 while its $448.2m liquidity backs a definitive 2027 melanoma readout and planned BLA.
Moderna rallies into a landmark FDA advisory vote on its mRNA seasonal flu vaccine
Moderna (MRNA) rallies as an FDA advisory committee weighs its mRNA seasonal flu vaccine mFlusiva, the first such vote, with a decision due August 5. Full analysis.
Moderna (MRNA) and Merck (MRK) cancer vaccine sustains benefit at five years, but investors stay cautious
Moderna and Merck's mRNA cancer vaccine sustained a 49% reduction in melanoma recurrence at five years, but MRNA fell as investors weigh near-term pressures.
Moderna faces fresh mRNA patent assault from CureVac as BioNTech tightens legal grip on COVID-19 vaccine royalties
Moderna just settled $950 million in mRNA litigation. Now BioNTech-owned CureVac wants Spikevax royalties too. The patent war is widening.
GSK wins FDA approval to extend Arexvy RSV vaccine to at-risk adults aged 18 to 49, opening 21 million-strong US market
FDA expands Arexvy approval to at-risk adults 18-49, opening 21M-strong US market. Read what this means for GSK, Pfizer, Moderna, and the RSV vaccine landscape.
Moderna shakes up leadership as COVID vaccine demand wanes—can new R&D head realign its future?
Find out why Moderna, Inc. is replacing its medical chief with a development leader and what it means for the company’s post-COVID pipeline strategy.
Five-year data boosts Moderna and Merck’s neoantigen vaccine strategy in adjuvant melanoma
Moderna and Merck reveal 5-year data showing 49% reduction in melanoma recurrence with their mRNA-4157 and KEYTRUDA combo. Read more on what’s next.
Why Merck’s MSD is paying up to $600m for Evaxion’s undisclosed vaccine candidate EVX-B3
MSD licenses Evaxion’s AI-discovered vaccine EVX-B3 with $7.5M upfront and up to $592M in milestones—why this risky biotech bet could redefine vaccines.